Join to View Full Profile
2002 Holcombe BlvdBLDG 109 ROOM 217Houston, TX 77030
Phone+1 713-791-1414
Fax+1 713-578-5859
Dr. Shin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am board certified internist, hematologist and medical oncologist, trained at David Geffen School of Medicine at UCLA. I earned PhD in Tumor Immunology under the Dr. Antoni Ribas' mentorship via UCLA STAR (specialty training and advanced research) program and joined UCLA/VA as an Assistant Professor-in-Residence in 2017 and recently joined Houston VA/Baylor College of Medicine. My main interest of research is to understand the mechanisms of resistance to immunotherapy and develop new therapeutic approach for patients with lung cancer and melanoma.
Education & Training
- University of California, Los AngelesPhD, Tumor Immunology, 2013 - 2017
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2007 - 2012
- Kyung Hee University College of MedicineClass of 2002
Certifications & Licensure
- CA State Medical License 2012 - 2026
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- VA BLR&D Merit Review Award VA ORD
- VA CSR&D Merit Review VA ORD
- DoD Melanoma Translational Research Award DoD, 2021
- Join now to see all
Clinical Trials
- EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer Start of enrollment: 2025 Apr 28
Roles: Contact, Principal Investigator
- Repositioning Immunotherapy in VetArans With Lung Cancer Start of enrollment: 2024 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- CRE25-050: Durable Response to Immunotherapy Rechallenge With Double Immunotherapy for a Patient With Advanced Non-Small Cell Lung Cancer.Jason T Huynh, Rui Li, Daniel S Shin
Journal of the National Comprehensive Cancer Network. 2025-03-28 - Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.Daniel Sanghoon Shin, Daniel Sanghoon Shin, Saroj Basak, Mysore S Veena, Begoña Comin-Anduix
Cancer Medicine. 2024-05-01 - Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail.Mysore S Veena, Jungmo J Gahng, Mustafa Alani, Albert Y Ko, Saroj K Basak
Cancer Research Communications. 2024-03-08
Journal Articles
- Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancerMysore S Veena, Santanu Raychaudhuri, Saroj K Basak, Natarajan Venkatesan, Parameet Kumar, Roopa Biswas, Rita Chakrabarti, Jing Lu, Trent Su, Marcus Gallagher-Jones, M..., Journal of Biological Chemistry, 12/11/2020
- Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, Megan Wind-Rotolo, Ameya Champhekar, Egmidio Medina, Davis Y Torr..., Cancer Cell, 10/12/2020
- A randomized, phase 1, placebo‐controlled trial of APG‐157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor‐associated m...Saroj K Basak, Alakesh Bera, Alexander J Yoon, Marco Morselli, Chan Jeong, Anela Tosevska, Tien S Dong, Michael Eklund, Eric Russ, Hassan Nasser, Venu Lagishetty, Rong..., Cancer, 4/15/2020
- Join now to see all
Abstracts/Posters
- Impact of a pathologist-driven molecular testing protocol on veterans with non-small cell lung cancerRui Li, M Carmen Frias Kletecka, Daniel Sanghoon Shin, ASCO Annual Meeting 2023, abstract_ePoster, 5/31/2023
- Enhanced tumor control with a combination of APG-157 and immune checkpoint inhibitors for head and neck cancerDaniel Sanghoon Shin, Saroj K Basak, Mysore S Veena, Begoña Comin-Anduix, Arjun Bhattachrya, Tien Dong, Luis Z Avila, Marilene Wang, Eri Srivatsan, ASCO Annual Meeting 2022, Chicago, IL, 6/2/2022
- Phenotypic characteristics of T cells co-expressing SOX2, OCT3/4, and NANOG9. Michael Cerniglia, Helena Escuin-Ordinas,,Caroline Porter, Maria Aleshin, Gardenia Cheung-Lau, ZoranGalic, Inbal, Daniel Sanghoon Shin, Oritz Rosenblatt-Rosen, Anto..., Cancer Research, 2021
- Join now to see all
Press Mentions
- Protein associated with a neurodegenerative disorder may also play a role in preventing the spread of cancerFebruary 29th, 2024
- UCLA Researchers Presenting Work at ASCO Annual MeetingJune 3rd, 2022
- Scientists discover why some cancers may not respond to immunotherapyFebruary 27th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- International Association for the Study of Lung CancerMember
- Society for Melanoma ResearchMember
Other Languages
- Korean
External Links
- Researchgatehttps://www.researchgate.net/profile/Daniel-Shin
- google scholarhttps://scholar.google.com/citations?user=FJ-Mc8kAAAAJ&hl=en
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: